发明公开
- 专利标题： INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
- 专利标题（中）： 吲唑，CCR1受体拮抗剂
-
申请号： EP09739468.8申请日： 2009-04-23
-
公开(公告)号： EP2285783A1公开(公告)日： 2011-02-23
- 发明人: DISALVO, Darren , KUZMICH, Daniel , MAO, Can , RAZAVI, Hossein , SARKO, Christopher , SWINAMER, Alan, David , THOMSON, David , ZHANG, Qiang
- 申请人： Boehringer Ingelheim International GmbH , Boehringer Ingelheim Pharma GmbH & Co. KG
- 申请人地址： Binger Strasse 173 55216 Ingelheim DE
- 专利权人： Boehringer Ingelheim International GmbH,Boehringer Ingelheim Pharma GmbH & Co. KG
- 当前专利权人： Boehringer Ingelheim International GmbH,Boehringer Ingelheim Pharma GmbH & Co. KG
- 当前专利权人地址： Binger Strasse 173 55216 Ingelheim DE
- 代理机构： Hammann, Heinz
- 优先权： US48678 20080429
- 国际公布： WO2009134666 20091105
- 主分类号： C07D231/56
- IPC分类号： C07D231/56 ; C07D401/12 ; A61K31/416 ; A61P19/02 ; A61P25/28
摘要：
Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
公开/授权文献
- EP2285783B1 INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS 公开/授权日：2014-05-21
信息查询
